INTRODUCTION

Moritz Kaposi was a Hungarian physician and dermatologist who described a kind of skin tumor initially in 1872 that received his name later as Kaposi sarcoma (KS).\(^1\) In fact, it was Sternberg who gave the name as Kaposi sarcoma in 1912.\(^2\) But, it took nearly more than 100 years we discovered the causal organism of Kaposi’s sarcoma as HHV-8 in 1994.\(^3\) This is a kind of indolent angioproliferative spindle cell tumor cancer developed from endothelial and immune cells under the skin and soft tissues caused by the human herpes virus-8 or Kaposi’s sarcoma herpesvirus (KSHV).\(^3-5\) KS is a multicentric vascular tumor of mesenchymal origin derived due to the hyperplasia affecting the blood vessels developing on soft tissues in multiple areas of the entire body at once.\(^6-10\)

Further, as the Kaposi’s sarcoma herpesvirus (KSHV) is easily transmitted either sexually via blood and saliva or vertically through parturition, the act of childbirth from mother to her baby;\(^11-17\) it may lie dormant or replicated to cause cancer in human. This has usually been observed that the persons who are immunocompetent can carry the load of KSHV without any problem, but it triggers the Kaposi’s sarcoma in immunocompromised individuals. This is most commonly developed in either immunodeficient or the patients kept under immunosuppressant medications.\(^18,19\) The present review on Kaposi’s sarcoma is prepared in the light of recent researches done so far in the field of viral origin of cancer. In the present review, clinical presentation, histopathology, stages and the types of Kaposi’s sarcoma with the treatment of the same disease have been discussed as under:

CLINICAL PRESENTATION

Clinically, there are four types of Kaposi’s sarcoma developed in human as chronic or European, endemic or African, transplant-associated or iatrogenic and AIDS-related or epidemic.\(^20,21\) The diagnosis of Kaposi’s sarcoma is based on the visual inspections of characteristi-
cally colored, cutaneous, non-itchy, painless and even non
dangerous spots appeared on skin. These spots are red or
purple on white skin and blue brown or black on dark skin.
These lesions are found on face including nose, around the
eyes, ears and lips; oral cavity including gingiva, palate,
tongue and buccal mucosa and the lower extremities or
lower limbs. Early on, these lesions are usually painless but
when bleed or ulcerated over time become painful. Most
specifically the lesions present in the areas of legs or groin
may cause the feet to swell moving very painfully.19-23

Further, these lesions are also found on some internal organs,
especially on the lungs and the gastrointestinal tract. If the
virus infects the lungs, it often quickly gets worse, causing
respiratory failure and death.22 Similarly, the infection taking
place in digestive system shows no symptoms at all except
the pain in the stomach until it becomes very advanced. In an
advanced stage, intestinal obstruction, bleeding and bloody
stool may come out during defecation. But, despite all these
complications, a patient suffering from gastrointestinal Ka-
posi sarcoma looks like as normal as was being before 5 years
of infections. It means that even after 5 years of diagnosis a
person with KSHV looks like a normal average person. And,
it all happens due to the differential medications provided to
the patient that often responding well in time.23-25

In addition, the patients suffering from Kaposi’s sarcoma
may also show some associated symptoms such as swollen
lymph nodes, cough, fever, fatigue, loss of appetite, weight
loss, edema in foot, nausea, painful stomach, and vomiting.
Similarly, the KS life-threatening conditions may also occur
as difficult swallowing, intolerable belly pain with bloody
defecation, intestinal blockage, severe swelling in upper and
lower limbs, face or scrotum, severe coughing and the short-
ness of breath.24

Sometimes, the lesion of KS also arises as a systemic in-
flammatory condition due to the physical stimuli precisely at
the site of trauma such as injury, surgical or other wounds is
characteristically known as koebner’s phenomenon. The eti-
opathology of this phenomenon is not yet known. Although,
this is a rare phenomenon in connection with KS; the koeb-
nerization has also been documented in several other skin
diseases, including vitiligo, psoriasis, lichen planus, and vi-
ral warts.25

**Histopathology of the Disease**

The histopathology of Kaposi’s sarcoma shows red cells
in slit like spaces formed by atypical spindle cell prolifera-
ton of endothelial and associated inflammatory cells. These
cells grow faster and survive for a longer period of time. The
KSHV has been isolated in almost all the cases of Kaposi’s sarcoma.26,27 The KSHV proteins in cancer cells and Periodic-acid-Shiff (PAS) reagent positive hyaline bodies are also seen in the cytoplasm.9,28

**Stages of Kaposi’s sarcoma**

Depending upon whether the Kaposi’s sarcoma is localized,
developing, external, or immunosuppressed, there have been
various attempts to classify the stages of Kaposi’s sarco-
ma.26,29,30-32 On the basis of lesions in lymph nodes, the stages
disease distribution and the clinical pace of progression,
the Kaposi’s sarcoma is further diagnosed histologically as under:

**Stage I  Maculonodular stage**

Small macules and nodules are confined to appear only on
the lower extremities.

**Stage II  Infiltrative stage**

The plaques are formed on the same lower extremities. Sometimes, they are still associated with small nodules.

**Stage III  Florid Stage**

Often ulcerated angiomatous multiple plaques and nodules are found.

**Stage IV  Disseminated Stage**

Multiple angiomatous nodules and plaques extending be-
yond the lower extremities.

**Types of Kaposi’s sarcoma**

Epidemiologically, the Kaposi’s sarcoma can primarily be
categorized into four types ranging from minimal mucocuta-
aneous lesions to extensive organ involvement. The different
types of KS are based on different populations it captured in,
but changes within the KS Cells are more or less similar20.
They are of four types given as under:

1. Sporadic, classic (Mediterranean), European, chronic
type of Kaposi’s sarcoma.
2. Endemic, African Lymphadenopathic type of Kaposi’s
sarcoma.
3. Transplant associated (Iatrogenic) Immunoocompro-
mised Kaposi’s sarcoma.
4. Epidemic, AIDS related Acquired Immuno deficient
Kaposi’s sarcoma.33-38

**Sporadic, classic (Mediterranean), European, chronic
type of Kaposi’s sarcoma**

This type of KS is primarily occurred in the eastern European
population, Ascanajee Jews and Mediterranean descent.39-42
Elderly men with weak immunity between 50 to 70 years of
age are more affected than female.37 Chronic Kaposi’s sar-
coma usually has silent, protracted or indolent course and is
usually limited to the skin. It slowly progresses over many
years and often is not the cause of death. As this is non-
aggressive and slow growing KS, the lesions do not grow
as quickly, and new lesions do not develop as often. They
have solitary, one or more lesions on legs ankles or soles48.
Recently, a new drug named sirolimus has been introduced. Skin lesions are mostly found on the distal lower extremities or lower limbs. This form of disease rarely has lymph node, mucous membrane or visceral involvement. Oral mucosa is sometimes affected. In addition, the visceral lesions are usually asymptomatic and discovered only by autopsy. Clinically, gastrointestinal bleeding may occur. Approximately, one third of same KS patients may also develop another malignancy in future as non-Hodgkin lymphoma.

**Endemic, African, Lymphadenopathic type of Kaposi’s sarcoma**

This is an endemic African type of Kaposi’s sarcoma mainly found in males under the age of 40, mostly in countries of Malawi, Uganda, Swaziland, Zambia and Zimbabwe. Quite a good number of children of both sexes (approximately 70%) before attaining the age of puberty have also been reported to develop the KS with absolute mortality within three years. It has also been observed that in all these cases, only visceral nodes were affected. The cutaneous lesions were all absent in children but may appear in adults. The malaria and malnutrition prevalent in the region have also been reported to play some role in developing the KS as it weakens the children’s immunity severely.

**Transplant associated (iatrogenic), Immuno-compromised Kaposi’s sarcoma**

Kaposi’s sarcoma is also developed in those who have undergone solid organ transplantation receiving immunosuppressive therapy like the excessive use of cyclosporin A medication. It usually develops within two years of organ transplantation. This is an aggressive type of cancer affecting the lower distal extremities, visceral organs, and lymph nodes. However, the individuals born with congenital immunodeficiency are not at the elevated risk of developing Kaposi’s sarcoma. Recently, a new drug named sirolimus has given rather better results acting as antitumor and immunosuppressant both at a time. As this kind of KS affects the people who have had undergone organ transplantation taking immunosuppressive drugs to slow down their immune system, this is now being observed that lowering the dose of immunodrugs makes the KS lesions either go away or get smaller. The greater the immunosuppression, the more extensive and aggressive KS will be.

**Epidemic, AIDS-related Acquired Immunodeficient Kaposi’s sarcoma**

Another type of Kaposi’s sarcoma is a type of cancer that people with AIDS often get. Here KS is an AIDS defining condition. It means that an HIV positive person suffering from KS is definitely has progressed to AIDS. But, on the other hand, a person having been suffering from KS may not be suffering from AIDS. KS can also develop in an otherwise healthy person as well. This is clinically most aggressive and common opportunistic malignancy in HIV patients worldwide, occurring mostly in Africa and the USA. In the 1980s, AIDS related KS was very common in the USA. Similarly, this has also been one of the most common cancers in Uganda and Zambia, especially in children. The risk groups are gay and heterosexual men and women. But, it remains prevalent amongst men who have sex with men. All of them were HIV positive. But, now a very different type of Kaposi’s sarcoma has also been developing in male homosexuals who are HIV negative.

Since the KSHV is an oncogenic virus, the AIDS related KS has gained much attention due to its abnormal pathogenicity in human. It has been observed that at least three genes are responsible for the cause of KS in AIDS patient. They are named as ORF71, ORF72, and ORF73. With both localized and disseminated cutaneous involvement, the AIDS related KS often initially involves the lymph nodes, which is later on disseminated to various parts of the viscera. Generally, the pulmonary and gastrointestinal mucocutaneous lymph nodes are involved. Oral Kaposi’s sarcoma in acquired immunodeficiency syndrome have also been reported.

In the early 1980s, KS was one of the most frequent malignancies reported in AIDS patient before the introduction of antiretroviral therapies. Further, in United States, treating the HIV patients with highly active antiretroviral therapy (HAART) has resulted in the fewer cases of AIDS associated KS but in rest parts of the world where HAART services are not easy to provide, KS in AIDS patients have advanced quickly. Kaposi’s sarcoma has rarely been reported from India. The first case of AIDS related KS from India was reported in 1993, and since then only 16 cases have been reported.

**TREATMENT OF THE DISEASE**

Unfortunately, there is nothing available at present as treatment to kill the KSHV absolutely, instead of only alleviating the symptoms to slow down the disease progression. Similarly, there is no any routine method for identifying the KS in an individual except the antibody test. Nowadays, KS diagnosis in lesion specimens usually requires not only histological and immunohistochemical characterization but also HHV-8 detection using new molecular biology. Similarly, an oncologist and cancer expert can only identify the lesions present on the body. This is also quite unfortunate for us that sometimes a patient himself do not require any treatment as initially the lesions are otherwise painless. One of the oldest drugs to treat the lesions of Kaposi sarcoma is thalidomide. The drug has helped in shrinking the lesions of KS. But, as the drug has got some serious side effects, the other drugs like lenalidomide and pomalidomide are being studied for the same purposes. Angiogenesis inhibitors blocking the growth of blood vessels within tumors may also treat the le-
sions of KS. The drug named bevacizumab is one of them. The other drugs like sirolimus and everolimus are being studied further.

Further, the treatment options are more or less found similar to those recommended for other types of cancer such as surgical excision, radiation, chemotherapy, electrochemotherapy to use electric impulse in injecting the chemo drugs into tumors effectively, such as vincristine, vinblastine, Vincaalucoblastin, bleomycin and doxorubicin. Other treatment modalities are cutaneous cryosurgery, cryotherapy in which the lesions are freezeed using liquid nitrogen, use of cytokine inhibitors, immunotherapy including interferon, antiviral medications including Zidovudine, ganciclovir, Valganciclovir, cidofovir, and the topical application of alitretinoin gel (Panretin).

In addition, it has also been observed that some specific drugs commonly used for cancers are also being studied for use against Kaposi’s sarcoma such as paclitaxel, docetaxel and imatinib. Similarly, antiretroviral therapy has also been found to be the best way to treat the Kaposi’s sarcoma. It has not only even clear up the skin lesions but to have lowed the cases simultaneously. While infection of KSHV in human is estimated to account for nearly >44000 new cancer cases and 20,000 deaths globally every year, their efforts to develop vaccines are limited.

Since Kaposi sarcoma is not a curable disease, it could be treated to a limited extent to control the symptoms. The choice of treatment modalities depends upon the extent of the disease. Though it often progresses slowly, KS can ultimately be fatal. One should always seek treatment for KS. Further, as the indolent KS appears usually in older people taking many years to develop and grow, many people die of some other parainfections before their KS becomes serious enough to be fatal. Similarly, as the AIDS related KS is now treatable and not a cause of death by itself, we should nothing more to worry about it except to be alert in the future.

Kaposi’s sarcoma herpesvirus (KSHV) has been isolated in nearly all patients tumor suffering from the same cancer. This is spindle cell tumor thought to be derived from endothelial cell lineage. It arises as a cancer of lymphatic endothelium in vascular channels which are filled with blood cells giving the tumor its characteristic bruise-like appearance. The highly vascular network of KS tumor leaked R.B.C. in the surrounding tissues causing the tumor black in colour developing the inflammation and pain in the lesions.

Further, there are four types of Kaposi sarcoma that have so far been described in literature they are European or classic, endemic or African, transplant-associated and AIDS-related. Generally, it has been observed that Kaposi’s sarcoma is more linked to either immunocompromised patients infected with AIDS or had undergone organ transplantation taking immunosuppressive medications. The HHV-8 virus has also been found to be involved in producing some rare cancer like a blood cancer known as primary effusion lymphoma and multicentric Castleman disease. This is a sexually transmitted virus but can also be spread by some other ways also as direct contact through blood and saliva. Since, all forms of KS are manifested in the oral cavity; the KSHV is more easily being transmitted via saliva as well.

CONCLUSION

Cancer is an outcome of viral infection. It starts as a chronic inflammation (Kapositis) which ultimately produce Kaposi sarcoma. KS is a relatively large, linear double-stranded DNA tumor virus that transforms the cells in such a way that it multiplied indefinitely to live longer which eventually develops to form cancer, but it does not mean that all infected individuals will develop the cancer, appearing that some other factors are also required for it to develop. We opined, as the KS has a variable course and is not curable, it can possibly be treated and controlled symptomatically for a longer period of time. Finally, we should promote the public awareness using media for early detection and diagnosis of Kaposi’s sarcoma, especially in Africa.

Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>KSHV</td>
<td>Kaposi’s sarcoma herpes virus</td>
</tr>
<tr>
<td>AIDS</td>
<td>Acquired immune deficiency syndrome</td>
</tr>
<tr>
<td>KS</td>
<td>Kaposi’s sarcoma</td>
</tr>
<tr>
<td>PEL</td>
<td>Primary effusion lymphoma</td>
</tr>
<tr>
<td>MCD</td>
<td>Multicentric Castleman’s disease</td>
</tr>
<tr>
<td>HHV</td>
<td>Human herpesvirus</td>
</tr>
<tr>
<td>PAS</td>
<td>Periodic-acid-Schiff reagent</td>
</tr>
<tr>
<td>HIV</td>
<td>Human immunodeficiency virus</td>
</tr>
<tr>
<td>HAART</td>
<td>Highly active antiretroviral therapy</td>
</tr>
<tr>
<td>RBC</td>
<td>Red blood corpuscles</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic acid</td>
</tr>
</tbody>
</table>

Perspectives

Kaposi sarcoma is a rare, slow growing tumor cancer that develops underneath the skin with reddish-purple or blue-brown in colour lesions. These lesions are mainly found on the face, nose, legs, and around the anus. Some internal organs, especially the lungs and gastrointestinal tract are also affected. The gastrointestinal tract lesions are typically symptomless. Rarely, they may lead to bloody stools, pain, diarrhea or physical obstruction. But, the lung infection usually causes breathlessness due to blockage. A lung bleeding lesion may leak blood with mucus, which the individual then coughs up.
ACKNOWLEDGEMENTS

This piece of research work is dedicated to the memory of my maternal grandfather marhoom Hazi Mohammad Shakoor. The author acknowledges the help received from scholars whose articles are cited in references to this manuscript. The authors are also grateful to the institution concerned for providing us with necessary facilities during this research work.

Financial support: No Financial support was granted during the course of this research work.

REFERENCES


Gurievich VE, Lakovleva LS, Kadyrova EL. Antibodies to herpesvirus type 8 in Kaposi’s sarcoma patients and controls in Russia. Vopr Virusol 2003;48:19-22.


Agarwala MK, George R, Sudarsanam TD, Chacko RT, Thomas M, Nair S. Clinical course of Kaposi’s sarcoma in a HIV and